公开(公告)号：US08894999B2

公开(公告)日：2014-11-25

申请号：US13936084

申请日：2013-07-05

Applicant: Biogen Idec MA Inc.

Inventor： Sha Mi ,  Kenneth J. Rhodes ,  R. Blake Pepinsky

IPC: A61K39/395 ,  A61K39/00 ,  A61K38/00 ,  C07K14/00 ,  C12N15/113 ,  A61K31/713 ,  A61K38/17 ,  C07K16/28 ,  C12N15/11 ,  A61K31/7088 ,  C07K14/705

CPC classification number: C07K16/2878 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K38/177 ,  A61K39/39541 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/70578 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的死亡受体-6（DR6）蛋白，现在已被证明对调节神经系统细胞凋亡是重要的。 此外，已经发现p75是DR6的配体。 因此，本发明涉及使用DR6和/或p75拮抗剂抑制DR6和p75相互作用的方法。 此外，本文所述的方法包括使用DR6拮抗剂（任选与p75拮抗剂组合）促进神经系统细胞存活的方法，以及任选地与p75拮抗剂组合施用DR6拮抗剂治疗神经变性病症的方法 。

公开(公告)号：US20140010826A1

公开(公告)日：2014-01-09

申请号：US13936084

申请日：2013-07-05

Applicant: Biogen Idec MA Inc.

Inventor： Sha MI ,  Kenneth J. Rhodes ,  R. Blake Pepinsky

IPC: A61K39/395 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/17

CPC classification number: C07K16/2878 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K38/177 ,  A61K39/39541 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/70578 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的死亡受体-6（DR6）蛋白，现在已被证明对调节神经系统细胞凋亡是重要的。 此外，已经发现p75是DR6的配体。 因此，本发明涉及使用DR6和/或p75拮抗剂抑制DR6和p75相互作用的方法。 此外，本文所述的方法包括使用DR6拮抗剂（任选与p75拮抗剂组合）促进神经系统细胞存活的方法，以及任选地与p75拮抗剂组合施用DR6拮抗剂治疗神经变性病症的方法 。

公开(公告)号：US20150203585A1

公开(公告)日：2015-07-23

申请号：US14523451

申请日：2014-10-24

Applicant: Biogen Idec MA Inc.

Inventor： Sha MI ,  Kenneth J. Rhodes ,  R. Blake Pepinsky

IPC: C07K16/28 ,  A61K31/7088

CPC classification number: C07K16/2878 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K38/177 ,  A61K39/39541 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/70578 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的死亡受体-6（DR6）蛋白，现在已被证明对调节神经系统细胞凋亡是重要的。 此外，已经发现p75是DR6的配体。 因此，本发明涉及使用DR6和/或p75拮抗剂抑制DR6和p75相互作用的方法。 此外，本文所述的方法包括使用DR6拮抗剂（任选与p75拮抗剂组合）促进神经系统细胞存活的方法，以及任选地与p75拮抗剂组合施用DR6拮抗剂治疗神经变性病症的方法 。